This review highlights the complex management of atrial fibrillation in cancer patients, emphasizing drug-drug interactions with targeted therapies and the challenges of anticoagulation.
Answers are grounded in this paper and cite their sources.
Complicates AAD selection and anticoagulation decisions in cancer patients with AF; leaves open optimal strategies pending prospective data.
Atrial fibrillation (AF) is frequently observed in patients being treated for cancer and can lead to increased morbidity and mortality in this population. With the use of newer, targeted cancer therapies, several drug-drug interactions have emerged that complicate the use of antiarrhythmic drugs (AADs) in patients with active malignancy. Moreover, specific targeted therapies such as ibrutinib may contribute directly to the development of AF. The decision to pursue systemic anticoagulation can be challenging in patients with malignancy due to a number of factors, including the need for frequent procedures, the presence of malignancy-related risk factors for bleeding, and limited data regarding the safety of the novel oral anticoagulants (NOACs) in cancer patients. This review describes the challenges associated with AF management in patients with cancer and highlights a number of important drug-drug interactions that can impact patient management.
No takes yet. Share an insight, caveat, or question.
Asnani et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: